Among those studies, the anti-HER2 antibody trastuzumab was functionalized with two cationic peptides (NLS5-10 or TAT1-3) to improve the nuclear uptake in HER2-positive breast cancer, but this effect was limited and nonspecific [23]. Here, ERBB2 is linked to breast carcinoma.